Skip to main content
. 2018 Dec 11;9(97):36929–36944. doi: 10.18632/oncotarget.26405

Figure 1. Graphic representation of the clinical progression of patients with LOH in the HLA region.

Figure 1

(A) Patient 10, (B) Patient 9 and (C) Patient 22. Lena: Lenalidomine; NHR: No Hematological Response; CHR: Complete Hematological Response; 5-Aza: 5-Azazitidine; CT: Chemotherapy; MRD: Minimal Residual Disease.